Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHA:600671)
China · Delayed Price · Currency is CNY 22.52
0.00 (0.00%)
Sep 14, 2026, 3:00 PM CST
SHA:600671 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 207.57 | 211.7 | 216.91 | 121.52 | 107.97 | 146.55 |
Other Revenue | -0.06 | 0.06 | 0.39 | 0.26 | 0.94 | 0.52 |
| 207.51 | 211.75 | 217.3 | 121.78 | 108.91 | 147.07 | |
Revenue Growth | -20.60% | -2.55% | 78.44% | 11.82% | -25.95% | -28.82% |
Cost of Revenue | 100.41 | 111.59 | 116.62 | 98.37 | 93.74 | 106.45 |
Gross Profit | 107.1 | 100.16 | 100.68 | 23.41 | 15.16 | 40.62 |
Selling, General & Admin | 84.87 | 81.59 | 65.84 | 47.37 | 51.52 | 63.18 |
Research & Development | - | - | 1.21 | 0.48 | 1.58 | 1.33 |
Other Operating Expenses | 2.39 | 2.56 | 1.9 | 1.05 | 0.95 | 1.25 |
Operating Expenses | 89.77 | 86.12 | 71.24 | 45.91 | 59.05 | 69.81 |
Operating Income | 17.33 | 14.04 | 29.44 | -22.5 | -43.89 | -29.19 |
Interest Expense | -3.94 | -7.2 | -5.56 | -7.19 | -7.4 | -7.35 |
Interest & Investment Income | 1.78 | 1.85 | 0.48 | 0.11 | 1.02 | 0.1 |
Other Non Operating Income (Expenses) | -3.08 | -0.17 | 4.87 | -2.53 | -2.74 | -0.33 |
EBT Excluding Unusual Items | 12.09 | 8.52 | 29.23 | -32.1 | -53.01 | -36.78 |
Impairment of Goodwill | - | - | -0.58 | - | -0.53 | -2.92 |
Gain (Loss) on Sale of Investments | -0.01 | - | - | -0.53 | - | - |
Gain (Loss) on Sale of Assets | 0.83 | 0.17 | -0.21 | 0.15 | -0.09 | 0.04 |
Asset Writedown | -0.72 | -0.93 | - | -6.01 | -17.24 | - |
Legal Settlements | -0.01 | - | - | - | - | - |
Other Unusual Items | -0.8 | 2.47 | 0.64 | 2.18 | -1.5 | 5.92 |
Pretax Income | 11.39 | 10.22 | 29.07 | -36.31 | -72.37 | -33.73 |
Income Tax Expense | 5.64 | 3.02 | 7.21 | 2.99 | 0.76 | -0.95 |
Earnings From Continuing Operations | 5.75 | 7.2 | 21.87 | -39.3 | -73.12 | -32.78 |
Minority Interest in Earnings | 7.93 | 10.42 | -6.62 | 1.02 | 5.61 | 2.98 |
Net Income | 13.68 | 17.62 | 15.25 | -38.28 | -67.52 | -29.8 |
Net Income to Common | 13.68 | 17.62 | 15.25 | -38.28 | -67.52 | -29.8 |
Net Income Growth | -68.91% | 15.59% | - | - | - | - |
Shares Outstanding (Basic) | 122 | 122 | 122 | 122 | 122 | 124 |
Shares Outstanding (Diluted) | 122 | 122 | 122 | 122 | 122 | 124 |
Shares Change | 0.03% | 0.01% | -0.01% | -0.00% | -1.92% | 1.13% |
EPS (Basic) | 0.11 | 0.14 | 0.13 | -0.31 | -0.55 | -0.24 |
EPS (Diluted) | 0.11 | 0.14 | 0.13 | -0.31 | -0.55 | -0.24 |
EPS Growth | -68.92% | 15.57% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 27.8 | -19.39 | -57.23 | -29.38 | -22.89 | -31.13 |
Free Cash Flow Per Share | 0.23 | -0.16 | -0.47 | -0.24 | -0.19 | -0.25 |
Gross Margin | 51.61% | 47.30% | 46.33% | 19.23% | 13.92% | 27.62% |
Operating Margin | 8.35% | 6.63% | 13.55% | -18.48% | -40.30% | -19.85% |
Profit Margin | 6.59% | 8.32% | 7.02% | -31.43% | -62.00% | -20.26% |
Free Cash Flow Margin | 13.40% | -9.16% | -26.34% | -24.13% | -21.02% | -21.17% |
EBITDA | 31.87 | 28.5 | 41.29 | -11.34 | -29.02 | -19.56 |
EBITDA Margin | 15.36% | 13.46% | 19.00% | -9.31% | -26.65% | -13.30% |
D&A For EBITDA | 14.54 | 14.46 | 11.85 | 11.16 | 14.86 | 9.64 |
EBIT | 17.33 | 14.04 | 29.44 | -22.5 | -43.89 | -29.19 |
EBIT Margin | 8.35% | 6.63% | 13.55% | -18.48% | -40.30% | -19.85% |
Effective Tax Rate | 49.55% | 29.55% | 24.79% | - | - | - |
Revenue as Reported | 108.16 | 211.75 | 217.3 | 121.78 | 108.91 | 147.07 |
Advertising Expenses | - | 2.65 | 1.19 | 0.9 | 0.77 | 0.46 |